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chologist conducted semi-structured individual interviews with 2 clinical experts 
and 30 patients in the UK recruited through general practitioners. Clinical experts 
were asked to identify key concepts attributable to the overactive bladder (symp-
toms). Patients were asked to describe their symptoms and impact on HRQL and 
rate them. All patient responses were coded using code frequency and bother rat-
ings. Results: Seven men, 23 women were interviewed; the majority of patients 
were older than 65 years. 50% of the patients were incontinent. Preliminary analysis 
suggests that OAB affects the patient’s quality of life on several aspect of their 
life: psychological (embarrassment and worry), occupational limitations, domes-
tic (usual activities) and limitations in leisure activities. All patients reported that 
feeling the need to go ‘‘too often’’ to the bathroom (urgency and frequency) led to 
significant limitations such as avoidance of any unplanned activities. HRQL con-
cepts were similar across the different age group. As expected, patients suffering 
from urgency incontinence reported this symptom as being the most impactful, 
especially in terms of embarrassment and worry. ConClusions: Although the 
impact of all OAB symptoms was found to be significant and similar across all 
patients regardless of their age, the greatest impact or burden of OAB was felt and 
reported by wet patients compared to dry patients.
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objeCtives: Bladder cancer (BC) is the fourth most common malignancies among 
men and it has high medical costs per-patient from diagnosis until death. Generally 
little is known about the burden BC imposes on patients’ health-related quality 
of life (HRQL) and the literature lacks detailed utility data for economic evalua-
tions in BC. The authors’ goal was to assess the HRQL and health status utility of 
BC patients. Methods: A cross sectional survey was performed in three hospital 
based urology centres. Adult patients with BC attending routine care were invited to 
participate in the study. Data on demographics, disease history and co-morbidities 
were obtained, validated versions of the EQ-5D and SF-36 generic questionnaires 
were applied. The UK tarrifs were used to calculate EQ-5D score and the SF-36 was 
converted to SF-6D utilities. Disease-specific HRQL was assessed by the FACT-BL 
questionnaire. Results: Altogether 98 patients (males 63.3%) were involved with 
mean age of 66.4 (SD= 8.6) and disease duration of 3.4 (SD= 3.0) years. The SF-36 
physical and mental health summary measures were 62 (SD= 24), 65 (SD= 24), 
respectively, the scores of the 8 domains were comparable to the > 65 years old 
general population’s results. The average SF-6D, EQ-5D and EQ VAS utility scores 
were 0.705 (SD= 0.145), 0.772 (SD= 0.252) and 68.8 (SD= 19.0). The difference of EQ-5D 
score compared to the age-matched population norm was not significant (p= 0.65). 
The FACT-BL physical, social, emotional and functional well-being scores were 
mean 23.1 (SD= 5.4), 20.6 (SD= 5.7), 18.1 (SD= 5.1) and 19.0 (SD= 6.7), the total score 
was 114.0 (SD= 23.5). ConClusions: According to our knowledge this study is the 
first to assess BC patients’ HRQL using diverse preference based measures. Further 
studies involving larger samples might increase our knowledge on the performance 
of these questionnaires in BC subgroups by disease stage, type of treatment and 
urinary diversion.
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objeCtives: The reluctance of those with overactive bladder OAB to seek medical 
advice can leave a considerable part of the population untreated, with significant 
costs for society. The present study investigates the burden of individuals who 
experience symptoms of OAB but are not treated. Methods: Data were taken 
from the 5EU (France, Germany, Italy, Spain, and UK) 2013 National Health and 
Wellness Survey (NHWS), a cross-sectional survey representative of the total adult 
populations in each 5EU market. 62,000 respondents self-reported physician diag-
nosis of various health conditions, including 1,347 who reported symptoms com-
patible with OAB. These respondents were compared to those who didn’t report 
symptoms of OAB. Variables of interest were demographics (age, gender, marital 
status, education, income and employment status), BMI, alcohol and smoke behav-
iour, health-related quality of life (HR-QoL), work productivity and activity impair-
ment (WPAI). Results: The OAB group, compared to the controls, was older (57 
vs. 47 years), with a lower education level (49.14% went to college vs. 54.49%), less 
were in a relationship (26.43% vs. 31.82%), less were employed (35.04% vs. 58.15%), 
more were obese (31.11% vs. 17.22%), they had lower HR-QoL (SF-36v2, PCS: 42.09 
vs. 51.36; MCS: 42.55 vs. 46.25; Utility: 0.62 vs. 0.73), had lower work productivity 
(overall work impairment of 34.46 vs. 20.03) and higher activity impairment (46.07 
vs. 24.35). All differences were significant (p< 0.001). ConClusions: Respondents 
reporting symptoms compatible with OAB but are not treated and would not be 
captured by clinical studies, are significantly worse-off than the rest of the popu-
lation, e.g. in their quality of life, income and work productivity. It is likely that 
undergoing treatment would benefit them and decrease health care costs.
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patients completed the SNM pre-implant evaluation; data from 265 subjects were 
included in EQ-5D or EIQ analyses. Matched paired t-tests compared EQ-5D scores 
and costs from baseline to each follow-up. Results: Baseline mean EQ-5D index 
score (n= 265) was 0.777. Index scores significantly improved (p< 0.05) from base-
line at each follow-up period [3-months (n= 247)= 0.850, 6-months (n= 246)= 0.828, 
and 12-months (n= 232)= 0.839]; the largest improvement in scores (0.073) was at 
3 months. The proportion of patients reporting no problems on the EQ-5D dimen-
sions of Usual Activities, Anxiety/Depression and Pain/Discomfort and Self-Care 
increased from 61.2% (baseline) to 72.0% (12 months); 57.3% to 69.4%; 40.9% to 50.9%, 
and 93.1% to 95.3%, respectively; the Mobility dimension had a non-significant 
decline (68.5% to 66.4%). At baseline, study subjects reported a 3-month average 
expenditure of $228 (US) for durable and disposable medical supplies and health 
service utilization; 74% of the expenditure was attributed to ER, hospitalization and 
outpatient health services use. Expenditures significantly declined (p< 0.05) by an 
average of $163 per 3-month period post-implant. ConClusions: After receiving 
SNM implant, EQ-5D index scores were significantly improved and self-reported 
durable and disposable medical supplies and health service expenses to manage 
OAB were significantly reduced.
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objeCtives: 1) To determine what is the utility change for kidney donors from 
before to 3 months after donation; 2) To determine the minimal important differ-
ence (MID) of a decrease (MIDe) in utility for kidney donors. Methods: We used 
data from a prospective multicenter observational study, measuring the Health 
Related Quality of Life (HRQoL) of kidney donors before and three months after 
transplantation. Utility scores were estimated using the SF-6D and EQ5D. Two 
methods were used to estimate the MIDe: i) the anchor-based method by the 
Global Rating of Change (GRoC) for donors rating their global health “somewhat 
worse” 3 months after donation; ii) the distribution-based method by the standard 
error of measurement (SEM). Results: In total, 211 donors for the EQ-5D and 192 
for the SF-6D completed the questionnaire. Results showed a significant (p< .0001) 
decrease in utility score at three months. The mean (SD) utility score before trans-
plantation was 0.932 (±0.091) with the EQ5D, and 0.834 (±0.085) using the SF-6D, 
and 0.882 (±0.151) and 0.757 (±0.118) respectively at three months with a significant 
decrease (< .0001). Half of donors (53.9%) rated their global health “about the same” 
and 35 (15.4%) “somewhat worse” at follow up. Using the GRoC method, the MIDe 
was -0.113 units for the EQ-5D and -0.128 units for the SF-6D. By the SEM method, 
MIDe was -0.076 for the EQ5D and -0.073 for the SF6D. More than third of patient 
rechead the MIDe using the SEM method. ConClusions: This study showed a 
significant descrease in utility score three months after donation in most donors 
while reporting their global health “about the same”. The MIDe can be used by 
clinician as a threshold to identify donors with a meaningful decrease in utility 
score in a short run after donation.
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objeCtives: Urinary incontinence (UI) is a public health issue with a considerable 
social and economic impact. It affects temporarily or permanently about 400 000-500 
000 adults in Hungary. The purpose of our study was to estimate the prevalence, 
consultation rates and treatment behaviour of the adult population. Methods: 
In 2012 a 15-item questionnaire survey was performed as a part of a mobile 
health unit screening “The comprehensive health test program of Hungary 2010-
2020”. Results: Altogether 13 355 respondents (60.4% female) completed the ques-
tionnaire, the mean age was 40.2 years (SD 12.2). The prevalence rate of UI was 9.7% 
(n= 786) of women and 3.8% (n= 200) of men. Consultation rates were 22.9% (n= 180) 
for women and 32.5% (n= 65) for men. Seventy-three women (40.6%) consulted a 
gynaecologist, 37 (20.5%) a GP, 46 (25.6%) an urologist and 24 (13.3%) consulted more 
than one physicians. Five men (7.7%) consulted a GP, 44 (67.7%) an urologist and 
16 (24.6%) didn’t answer. Among those who consulted a physician 52.2% (n= 94) of 
women and 66.2% (n= 43) of men found solution for their urinary symptoms. In the 
group of respondents who consulted a doctor (n= 245) the most common therapies 
were medications, surgical treatment, absorbent pads or any combination of the 
foregoing. In the group who self-managed their symptoms without consulting a 
doctor (n= 741) absorbent products and/or pelvic muscle training were the most 
frequently applied therapies. ConClusions: Our prevalence results are in line 
with the international UI screenings. We found low medical consulting rates and 
the majority of the respondents having symptoms used self-management tech-
niques for UI.
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objeCtives: To review and identify HRQL dimensions in dry and wet OAB patients 
through literature review and patient interviews. Methods: A literature review 
on OAB HRQL was performed using the EMBASE database. Specialized forums were 
also searched for relevant HRQL issues reported by OAB patients. A trained psy-
